Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI® Translational analyses show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback